Surgical Treatment of Liver Metastases of Gynecological Cancer: Local Treatment of a Systemic Disease

Eric Viberth, Denis Castaing

The interesting paper of Kollmar et al. [7] in the last issue of Onkologie very well summarizes the development of liver metastases in metastatic disease. In this work, they report on 43 patients that have been operated on for liver metastases of gynecological cancers between 2000 and 2007. More than 80% of these patients received chemotherapy before and after laparotomy, which allowed a curative liver resection in 30 patients. Except for 3 patients, all had metachronous disease with a mean delay of more than 6 years after resection of the primary tumor. Their postoperative mortality was lower than 10% and 4 patients had positive margins. Liver metastases of breast cancer represented the major subset of the patients of this series (62%). In this group, resection of liver deposits clearly improved the outcome with a 5-year overall survival of 50% compared to a median of survival of 7.4 months without resection. The small number of patients treated for liver metastases of ovarian (n = 8) or uterine cancer (n = 8) makes it difficult to interpret the results that showed no clear advantage of liver surgery compared to explorative laparotomy. It is a pity that the results have not been stratified according to the primary tumors.

The major interest of this paper is to describe the results of a series of patients recently treated for liver metastases of breast cancer and within a relatively short period (2000–2007). In fact, several series of this pathology are now available but all of these have covered long periods of inclusion. For instance, the two largest series include 69 and 108 patients, but the patients included were operated on between 1988 and 1999 [8] and 1984 and 2004, respectively [9].

Even though the present series of patients is small, it demonstrates of the end of a dogma. Surgical therapy now plays an important role in the treatment of cancer patients with apparent systemic disease spread, as in metastatic breast cancer. Approximately 50% of breast cancer patients develop metastases [10] and this series confirms that patients with liver metastases from breast cancer will probably more often be offered surgery. The benefit of neoadjuvant chemotherapy has been demonstrated only recently in patients operated for resectable colorectal liver metastases [11], soon the benefit of adjuvant surgery in patients treated by chemotherapy for metastases of breast cancer will become apparent.

Denis Castaing, M.D.
Hôpital Paul Brousse, Centre Hépato-Bilaire
12 Avenue Paul Vaillant Couturier
94804 Villejuif Cedex, France
Tel. +33 1 45 59-3000, Fax -3857
denis.castaing@pbr.aphp.fr
References


